Compare GKOS & KMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | KMX |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | 2015 | 2002 |
| Metric | GKOS | KMX |
|---|---|---|
| Price | $103.96 | $43.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | ★ $133.07 | $40.33 |
| AVG Volume (30 Days) | 662.2K | ★ 3.1M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.46 |
| Revenue | $507,442,000.00 | ★ $26,353,420,000.00 |
| Revenue This Year | $23.39 | N/A |
| Revenue Next Year | $27.46 | $0.73 |
| P/E Ratio | ★ N/A | $17.15 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $30.40 |
| 52 Week High | $130.23 | $82.79 |
| Indicator | GKOS | KMX |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 50.10 |
| Support Level | $81.54 | $42.97 |
| Resistance Level | $106.52 | $46.74 |
| Average True Range (ATR) | 3.58 | 1.69 |
| MACD | -1.81 | -0.00 |
| Stochastic Oscillator | 14.28 | 63.14 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.